Table 2.
Baseline characteristics according to the administered drug.
| Type of Drug | |||
|---|---|---|---|
| Overall, N = 32 1 | Antiviral, N = 12 1 | MAbs, N = 20 1 | |
| Gender | |||
| F | 14 (44%) | 4 (33%) | 10 (50%) |
| M | 18 (56%) | 8 (67%) | 10 (50%) |
| Age (years) | 8.5 (5.4, 10.7) | 8.5 (5.6, 11.7) | 8.5 (5.2, 10.3) |
| Age, categorical (years) | |||
| ≤2 | 4 (12%) | 1 (8.3%) | 3 (15%) |
| >2 | 28 (88%) | 11 (92%) | 17 (85%) |
| Weight (kg) | 24 (17, 42) | 23 (21, 45) | 24 (16, 31) |
| Baseline disease | |||
| Oncohematological | 22 (69%) | 10 (83%) | 12 (60%) |
| Solid Organ Transplantation | 4 (12%) | 0 (0%) | 4 (20%) |
| Other | 6 (19%) | 2 (17%) | 4 (20%) |
| COVID-19 vaccination | |||
| No | 30 (100%) | 11 (100%) | 19 (100%) |
| Steroid therapy | 13 (41%) | 4 (33%) | 9 (45%) |
| Polytherapy | 15 (47%) | 6 (50%) | 9 (45%) |
| COVID-19 symptoms | |||
| Asymptomatic | 11 (34%) | 6 (50%) | 5 (25%) |
| Mild symptoms | 21 (66%) | 6 (50%) | 15 (75%) |
| Off-label prescription | 27 (84%) | 11 (92%) | 16 (80%) |
| Creatinine (μmol/L) | 36 (26, 56) | 31 (22, 40) | 39 (28, 56) |
| AST (U/L) | 48 (30, 69) | 52 (34, 74) | 45 (31, 68) |
| ALT (U/L) | 42 (26, 78) | 45 (28, 87) | 41 (26, 71) |
Legend: 1 n (%); Median (IQR); MAbs: monoclonal antibodies; F: female; M: male; AST: aspartate aminotransferase; ALT: alanine aminotransferase.